Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $28M (down 28.6% year over year) with net income of −$41M.
Q3 2026 key financials · XBRL
- Revenue
- $28M
- −28.6% YoY · +37.5% QoQ
- Net income
- −$41M
- +49.2% YoY · +12.3% QoQ
- Operating margin
- -157.5%
- EPS (diluted)
- −$0.62
- +57.2% YoY · +16.2% QoQ
Source: XBRL data from the Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 10-Q on SEC EDGAR. USD.
Ginkgo Bioworks Holdings, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $27.7M, down $1.7M YoY from $29.4M, driven by reduced agriculture customer services
- Operating margin (157.5%) vs (280.1%) YoY, based on operating losses of $43.6M and $82.3M
- Cell engineering tools costs $1.8M vs $4.6M, benefiting from lower lab automation equipment expenses
- Cash, equivalents and marketable securities $285.4M, sufficient through at least the next 12 months
- Nine-month operating cash flow $(117.0)M, ATM proceeds $23.0M, expenditures expected to exceed revenue through next 12 months
Risk Factors
- No material changes to 2025 Annual Report risk factors
- Investment risk: potential loss of all or part of invested capital
- Business risk: adverse effects on prospects, financial condition, or operating results
- Carried-forward risk details unavailable in provided section
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Ginkgo Bioworks Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.